The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for EyePoint Pharmaceuticals. The maintained price target of $31 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.